Zevra Therapeutics Net Debt Growth & History (ZVRA)
Zevra Therapeutics's net debt was $800,000 for fiscal 2025.
View full Zevra Therapeutics company overviewZevra Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $800,000 | −$25.7M | −96.98% |
| 2024 | 2024-12-31 | $26.5M | $63.5M | — |
| 2023 | 2023-12-31 | −$37.0M | $27.2M | — |
| 2022 | 2022-12-31 | −$64.1M | $46.6M | — |
| 2021 | 2021-12-31 | −$110.7M | −$176.3M | — |
| 2020 | 2020-12-31 | $65.6M | −$11.2M | −14.55% |
| 2019 | 2019-12-31 | $76.7M | $13.1M | +20.55% |
| 2018 | 2018-12-31 | $63.6M | −$19.0M | −22.97% |
| 2017 | 2017-12-31 | $82.6M | $98.6M | — |
| 2016 | 2016-12-31 | −$15.9M | $15.0M | — |
| 2015 | 2015-12-31 | −$30.9M | −$21.1M | — |
| 2014 | 2014-12-31 | −$9.9M | — | — |
Zevra Therapeutics quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$143.8M | −$158.4M | — |
| Q1 2026 | 2026-03-31 | −$94.4M | −$118.9M | — |
| Q4 2025 | 2025-12-31 | $800,000 | −$25.7M | −96.98% |
| Q3 2025 | 2025-09-30 | $8.3M | $2.4M | +40.59% |
| Q2 2025 | 2025-06-30 | $14.6M | −$5.6M | −27.93% |
| Q1 2025 | 2025-03-31 | $24.5M | $66.1M | — |
| Q4 2024 | 2024-12-31 | $26.5M | $63.5M | — |
| Q3 2024 | 2024-09-30 | $5.9M | $48.2M | — |
| Q2 2024 | 2024-06-30 | $20.2M | $85.3M | — |
| Q1 2024 | 2024-03-31 | −$41.6M | −$2.6M | — |
| Q4 2023 | 2023-12-31 | −$37.0M | $27.2M | — |
| Q3 2023 | 2023-09-30 | −$42.3M | $26.3M | — |
| Q2 2023 | 2023-06-30 | −$65.1M | $10.1M | — |
| Q1 2023 | 2023-03-31 | −$39.0M | $59.8M | — |
| Q4 2022 | 2022-12-31 | −$64.1M | $46.6M | — |
| Q3 2022 | 2022-09-30 | −$68.6M | $61.2M | — |
| Q2 2022 | 2022-06-30 | −$75.2M | $55.3M | — |
| Q1 2022 | 2022-03-31 | −$98.7M | −$24.8M | — |
| Q4 2021 | 2021-12-31 | −$110.7M | −$176.3M | — |
| Q3 2021 | 2021-09-30 | −$129.8M | −$193.5M | — |
| Q2 2021 | 2021-06-30 | −$130.5M | −$194.5M | — |
| Q1 2021 | 2021-03-31 | −$73.9M | −$142.7M | — |
| Q4 2020 | 2020-12-31 | $65.6M | −$11.2M | −14.55% |
| Q3 2020 | 2020-09-30 | $63.7M | $60.7M | +2022.74% |
| Q2 2020 | 2020-06-30 | $64.0M | $61.9M | +2896.44% |
| Q1 2020 | 2020-03-31 | $68.7M | $72.7M | — |
| Q4 2019 | 2019-12-31 | $76.7M | $13.1M | +20.55% |
| Q3 2019 | 2019-09-30 | $3.0M | $793,000 | +35.95% |
| Q2 2019 | 2019-06-30 | $2.1M | $14.6M | — |
| Q1 2019 | 2019-03-31 | −$4.0M | $743,000 | — |
| Q4 2018 | 2018-12-31 | $63.6M | −$19.0M | −22.97% |
| Q3 2018 | 2018-09-30 | $2.2M | $9.9M | — |
| Q2 2018 | 2018-06-30 | −$12.5M | −$299,000 | — |
| Q1 2018 | 2018-03-31 | −$4.7M | $8.0M | — |
| Q4 2017 | 2017-12-31 | $82.6M | $98.6M | — |
| Q3 2017 | 2017-09-30 | −$7.6M | $13.1M | — |
| Q2 2017 | 2017-06-30 | −$12.2M | $13.3M | — |
| Q1 2017 | 2017-03-31 | −$12.7M | $62.9M | — |
| Q4 2016 | 2016-12-31 | −$15.9M | $15.0M | — |
| Q3 2016 | 2016-09-30 | −$20.7M | $37.1M | — |
| Q2 2016 | 2016-06-30 | −$25.5M | $38.7M | — |
| Q1 2016 | 2016-03-31 | −$75.7M | −$65.4M | — |
| Q4 2015 | 2015-12-31 | −$30.9M | −$21.1M | — |
| Q3 2015 | 2015-09-30 | −$57.9M | — | — |
| Q2 2015 | 2015-06-30 | −$64.2M | — | — |
| Q1 2015 | 2015-03-31 | −$10.2M | — | — |
| Q4 2014 | 2014-12-31 | −$9.9M | — | — |
Zevra Therapeutics net debt trends
Over the last five fiscal years, Zevra Therapeutics's net debt decreased from $65.6M to $800,000, a change of −$64.8M. The latest reported quarter, Q2 2026, shows −$143.8M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Zevra Therapeutics source filings ↗